Abstract
Cytokine-induced killer cells (CIK) are cytotoxic T cells, which have both NK and T cell properties. These cells are characterized by potent, non-MHC-restricted cytotoxicity and reduced alloreactivity, which make them appealing for use in adoptive immunotherapy of cancer and virus infections. In this study, CIK cells were generated by stimulating umbilical cord blood-derived mononuclear cells (UCB-MNCs) with interferon-gamma (IFN-γ) on day 0. Anti-CD3 antibody and interleukin-2 (IL-2) were added after 24 h at four different experimental concentration combinations in order to identify the optimal cytokine amounts for CIK cell proliferation. Cells were collected at four time points over a 21-day period (day 0, 7, 14, 21) for analysis of cell marker presentation using flow cytometry, as well as transcription-level cytokine production using RT-PCR. The results showed that in the 21-day culture, killer (LAK) cells, and cytokine-induced killer (CIK) cells. Among them, CIK cells appear to be the most promising cytotoxic effector cell type. CIK cells are a heterogeneous subset of T lymphocytes with NK functional properties. The qualifier “cytokine- induced killer” indicates that they are generated via administration of cytokines during in vitro culture [1, 2]. Cells which have the most potential effector function in CIK culture co-express CD3 and CD56 surface molecules; possess a potent, MHC-unrestricted tumor-killing ability; and significantly reduced alloreactivity [3]. CIK cells recognize tumor cells through the binding of CIK NKG2D receptors with tumor cell ligands such as MHC class I polypeptide- related sequences A and B (MICA and MICB); they then the average final expansion levels of 56 + CIK cell CD were in the range of hundredfold, accounted for 26% in the bulk culture. Most important, these cells strongly expressed granzyme B (80.87%), a potent factor involved in cell- mediated cytotoxicity. These CIK cells also transcriptionally overexpressed the three cytokine genes that produce IFN-γ, tumor necrosis factor-alpha (TNF-α), and IL-2; these are key for immune cell mobilization against tumors as well as foreign pathogens. Our research establishes an effective cytokine con- centration and time protocol for use in generation of CIK cells from UCB-MNCs, potentiating greater applications of CIK cell-adoptive immunotherapy in both research and clinical settings. Thus, the 3rd and 4th experimental conditions both stimulated CIK cell differentiation with 50 ng/ml of anti-CD3 antibody, but with IL-2 concentrations of 500 and 1000 U/ml, respectively.
Binh Thanh Vu and Quyen Thanh-Ngoc Duong are equally contributed to this work.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Arafar A (2014) Cytokine induced killer cell immunotherapy in cancer treatment: from bench to bedside. Biomed Res Ther 1(2)
Linn YC, Hui KM (2010) Cytokine-induced NK-like T cells: from bench to bedside. BioMed Research International
Sangiolo D et al (2008) Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int Immunol 20(7):841–848
Mehta BA et al (1995) Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+CD56+ killer cells. Blood 86(9):3493–3499
Pievani A et al (2011) Dual-functional capability of CD3+ CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR- mediated specific cytotoxicity. Blood 118(12):3301–3310
Schmidt-Wolf I et al (1993) Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine- induced killer cells. Exp Hematol 21(13):1673–1679
Baker J et al (2001) Expansion of cytolytic CD8+ natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon γ production. Blood 97(10):2923–2931
Ortaldo JR et al (1991) Comparative studies of CD3− and CD3+ CD56+ cells: examination of morphology, functions, T cell receptor rearrangement, and pore-forming protein expression. Cell Immunol 136(2):486–495
Schmidt RE et al (1986) A subset of natural killer cells in peripheral blood displays a mature T cell phenotype. J Exp Med 164(1):351–356
Schmidt-Wolf I et al (1991) Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174(1):139–149
Hoyle C et al (1998) Expansion of philadelphia chromosome-negative CD3+CD56+ cytotoxic cells from chronic myeloid leukemia patients. In Vitro In Vivo Efficacy Severe Combined Immunodeficiency Dis Mice 92:3318–3327
Lu P-H, Negrin RS (1994) A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 153(4):1687–1696
Durrieu L et al (2013) Cord blood-derived and peripheral blood-derived cytokine-induced killer cells are sensitive to fas-mediated apoptosis. Biol Blood Marrow Transplant 19(9):1407–1411
Introna M et al (2006) Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. Bone Marrow Transplant 38(9):621–627
Zhang Z et al (2015) Phenotypic characterization and anti-tumor effects of cytokine-induced killer cells derived from cord blood. Cytotherapy 17(1):86–97
Pham PV et al (2015) Production of dendritic cells and cytokine-induced killer cells from banked umbilical cord blood samples. Biomed Res Therapy 2(11):1–7
Introna M et al (2010) Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation. Biol Blood Marrow Transplant 16(11):1603–1607
Niu Q et al (2011) Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies. Int Immunopharmacol 11(4):449–456
Wang L et al (2014) Cord blood-derived cytokine-induced killer cellular therapy plus radiation therapy for esophageal cancer: a case report. Medicine 93(28):e340
Zhang Q et al (2014) Phenotypic and functional characterization of cytokine-induced killer cells derived from preterm and term infant cord blood. Oncol Rep 32(5):2244–2252
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Singapore Pte Ltd.
About this paper
Cite this paper
Vu, B.T., Duong, Q.TN., Le, P.M., Van Pham, P. (2018). Culture and Differentiation of Cytokine-Induced Killer Cells from Umbilical Cord Blood-Derived Mononuclear Cells. In: Vo Van, T., Nguyen Le, T., Nguyen Duc, T. (eds) 6th International Conference on the Development of Biomedical Engineering in Vietnam (BME6) . BME 2017. IFMBE Proceedings, vol 63. Springer, Singapore. https://doi.org/10.1007/978-981-10-4361-1_152
Download citation
DOI: https://doi.org/10.1007/978-981-10-4361-1_152
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-4360-4
Online ISBN: 978-981-10-4361-1
eBook Packages: EngineeringEngineering (R0)